The US government has launched “TrumpRx,” a drug discounting program it says will sharply reduce prescription costs for consumers. Announced amid debate over the cost of living ahead of the November 2026 midterm elections, the initiative is being promoted as ending “decades of overpayment” by aligning US prices with the lowest paid in other developed nations.
How the program works
TrumpRx is not an online pharmacy and does not sell drugs directly. It functions as a catalog that lists participating medicines and directs consumers to licensed stockists. Users can redeem coupons provided through the service to get discounts on out-of-pocket costs. Many coupons carry the group name MAHA, for the Make America Healthy Again campaign led by Health Secretary Robert F. Kennedy Jr.
Most-Favored-Nation pricing
The administration describes the deals with manufacturers as “Most-Favored-Nation” pricing: US prices for listed drugs should be no higher than the lowest price in comparison countries. The Department of Health and Human Services said those countries are drawn from high-income OECD nations whose per-capita GDP is at least 60% of the US. That list includes Luxembourg, Ireland, Switzerland, Norway, Iceland, Denmark, the Netherlands, Australia, Austria, Sweden, Belgium, Germany, Canada, Israel, the UK and Finland.
Products and participation
The initial catalog predominantly features Pfizer products but includes other brands. High-demand medicines such as weight-management injections (Wegovy, Zepbound), Ozempic, fertility drugs (Gonal-F, Cetrotide, Ovidrel), and medicines for menopause, depression, smoking cessation, kidney disease, thyroid disorders, high cholesterol, heart disease, HIV and diabetes appear on the list. The White House compared some prices to Canada — for example listing Gonal-F at $252 per unit versus $355 in Canada.
Why manufacturers joined
Manufacturers that agreed to join the program avoided the risk of expanded import tariffs threatened by the administration. Pfizer said it voluntarily entered the program and secured a three-year grace period during which its products would not face tariffs, conditional on further investment in US manufacturing.
Who benefits — and who may not
It is unclear how many Americans will see significant savings. Health economists warned when TrumpRx was announced that most people with employer-sponsored health insurance would likely pay less through their plans. The TrumpRx listings themselves caution, “If you have insurance, check your co-pay first — it may be even lower.”
Physician-researcher Matthew Klebanoff of the University of Pennsylvania called the program a step forward but said more is needed: “We need a more fundamental overhaul of how we set drug prices in the US. Right now, drug manufacturers can set prices to whatever the market will bear.”
Other limitations
– TrumpRx prices often apply to brand-name drugs. Generic alternatives may be substantially cheaper; Klebanoff noted Protonix is listed at about $200 per month on TrumpRx while generics cost roughly $10.
– Purchasing outside insurance plans means those payments do not count toward insurance deductibles or out-of-pocket maximums, potentially increasing total annual spending for some patients.
– It is unclear whether TrumpRx pricing will affect prices in other countries.
Political context
The rollout comes as the administration emphasizes tough measures on pharmaceutical companies. The program is being promoted partly as immediate relief for voters concerned about living costs ahead of the midterms, and has drawn public comments from administration figures — for example, CMS administrator Mehmet Oz quipped at the launch that lower fertility drug costs could mean “a lot of Trump babies.”
Edited by: Carla Bleiker